TTrialPathMatch Me to Trials
← Back to trials
RecruitingNeoplasms

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

Eligible age

18+ yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab

Sponsor: GlaxoSmithKline

You may qualify if…

  • ✓ Male or female participants at least 18 years of age (≥18 years)
  • ✓ Participants with histologically confirmed advanced/metastatic solid tumors, as defined per study phase and cohort, as follows:
  • ✓ Phase 1a:
  • ✓ 1. Participants with advanced/metastatic solid tumors.
  • ✓ 2. For monotherapy dose escalation: participants must have progressed on or become intolerant to all available SOC therapies.
  • ✓ 3. For combination dose escalation: participants must have received 3 or fewer prior lines of systemic anticancer therapy in the advanced/metastatic setting
  • ✓ Has at least 1 target lesion per RECIST 1.1, as determined by the investigator.
  • ✓ Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose.

You may not qualify if…

  • ✕ Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy.
  • ✕ Prior treatment with orlotamab, enoblituzumab, I-Dxd, or other B7-H3 targeted agents.
  • ✕ Primary brain tumor or evidence of brain metastasis (unless meeting the following criteria at the same time: asymptomatic; medically stable for at least 4 weeks prior to initial dosing; no steroid treatment required for at least 4 weeks prior to initial dosing; and no midline shift due to herniation); or untreated progression due to brain metastasis or primary brain tumor during or after the last treatment prior to screening; or evidence of meningeal/brainstem involvement; or evidence of spinal cord compression (detected by radiographic examination, symptomatic or not).
  • ✕ Any of the following cardiac examination abnormality:
  • ✕ 1. Has QT interval, corrected for heart rate (QTc) \>450 msec or QTc \>480 msec for participants with bundle branch block.
  • ✕ 2. Evidence of current clinically significant arrhythmias or ECG abnormalities (e.g., complete left bundle branch block, third-degree atrioventricular \[AV\] block, second-degree AV block, PR interval \>250 msec).
  • ✕ 3. Risk factors of prolonged QTc or arrhythmia events, such as heart failure, refractory hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death of any direct relative under 40 years old or any concomitant medications that prolong the QT interval.
  • ✕ 4. Left ventricular ejection fraction (LVEF) \<50%.

Where it's recruiting

California

Stanford

Colorado

Denver

Connecticut

New Haven

Indiana

Fort Wayne

Michigan

Detroit

New Jersey

New Brunswick

South Carolina

Myrtle Beach

Tennessee

Nashville

Texas

Austin · Dallas · San Antonio · Tyler

Utah

West Valley City

Virginia

Norfolk

Source: ClinicalTrials.gov · NCT06551142 · last updated 2026-05-22

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBO · TrialPath